

Subst. for form 1449/PTO <b>SUPPLEMENTAL          INFORMATION DISCLOSURE STATEMENT BY          APPLICANT UNDER 37 CFR 1.97(i)</b> <i>(Use as many sheets as necessary)</i>  June 24, 2009				<b>Complete if Known</b>	
				Application Number	10/735,863
				Filing Date	2003-12-15
				First Named Inventor	Lee Brettman
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	2	Of	3	Docket Number	079259-0237
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>					
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/R.S./	AV5	KOLA, Ismail, et al., "Can the pharmaceutical industry reduce attrition rates?", Nature Reviews, Drug Discovery, August 2004, pp 711-715, Vol. 3			
/R.S./	AW5	MA, Philip, et al., "Value of novelty?", Nature Reviews, Drug Discovery, August 2002, pp 571-572, Vol. 1			
/R.S./	AX5	FEAGAN, Brian G., et al., "Treatment of Ulcerative Colitis with a Humanized Antibody to the $\alpha_4\beta_7$ Integrin", N. Engl. J. Med., 352:2499-2507 (2005).			
/R.S./	AY5	FEAGAN, BG, et al., "Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin", Clin Gastroenterol Hepatol., 2008 Dec;6(12):1370-7 (Abstract only)			
EXAMINER			DATE CONSIDERED		
/Ronald Schwadron/			07/14/2009		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered.  
 Include copy of this form with next communication to applicant  
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached